Efficacy of 12 New-Generation Antidepressants Assessed

Efficacy of 12 New-Generation Antidepressants Assessed

 

Top 10 Most Read Articles by Psychiatrists:
  1.   Efficacy of 12 New-Generation Antidepressants Assessed  CME
A meta-analysis found clinically important differences among commonly prescribed antidepressants for both efficacy and acceptability, favoring escitalopram and sertraline for major depression.
  2.   Bipolar-I Patient Characteristics Associated With Differences in Antimanic Medication Prescribing
  3.   Second-Generation Antipsychotics Not All Superior to Older Drugs
  4.   FDA Expands List of Tainted Weight-Loss Products
  5.   TADS: Combination Therapy Achieves Remission Earlier Than Monotherapy in Adolescent Depression
  6.   Managing Unipolar Depression In Pregnancy
  7.   Effect of Exercise Training Intensity on Abdominal Visceral Fat and Body Composition
  8.   Overview of Obsessive-compulsive Disorder: An Expert Interview With Steven J. Brodsky, PsyD
  9.   Penile Size and Penile Enlargement Surgery: A Review
10.   Psychiatrist Receives Top Award From White House

Top 10 Most Read Articles by All Physicians:

  1.   A 25-Year-Old Woman With Hypotension and a Rash  CME/CE
A 25-year-old woman presents to the ED with a 2-day history of left lower quadrant pain, nausea, fever, and a rash. She was recently diagnosed with streptococcal pharyngitis. What is the diagnosis?
  2.   A 33-Year-old Woman with Sudden-Onset Severe Headache and Vomiting  CME
  3.   A 9-Year-Old Boy With a Recurrent Urinary Tract Infection and Failure to Thrive  CME/CE
  4.   Recurrent Syncope in a 10-Year-Old Boy  CME/CE
  5.   Economic Blues Trickle Down to Physicians 
  6.   AAPM 2009: New Guidelines on Chronic Opioid Therapy Presented 
  7.   A Puzzling Facial Rash on a 17-Year-Old Boy  CME/CE
  8.   ACPM 2009: USPSTF Updates Recommendations for Colorectal Cancer Screening 
  9.   A Fishy Business: Omega-3 Fatty Acids And Cardiovascular Disease 
10.   Increased Risk of Reinfarction With Clopidogrel and Proton-Pump Inhibitors 

Am J Psychiatry Future Table of Contents for 1 April 2009

Am J Psychiatry Future Table of Contents for 1 April 2009; Vol. 166, No. 4

 
Advertisement   
The American 
  Journal of Psychiatry -- Future Table of Contents Alert 
  
A new future TOC for American Journal of Psychiatry is available online for the issue:
  
1 April 2009; Vol. 166, No. 4
  

This Future Table of Contents is available online at: http://ajp.psychiatryonline.org/future/166.4.shtml

These articles have been accepted for this issue. Change is possible before publication.





  
Myrna M. Weissman
Am J Psychiatry 2009 166 (4)

The Future of Personality Disorders 
  in DSM-V? 
  
Andrew E. Skodol and Donna S. Bender
Am J Psychiatry 2009 166 (4)

Zeroing in on a 
  Schizophrenia Gene: A New Tool to Assess the Probability 
  
Susan E. Hodge and Robert Freedman
Am J Psychiatry 2009 166 (4)

The Amygdala in Autism: Not 
  Adapting to Faces? 
  
Micheal V. Lombardo, Bhismadev Chakrabarti and Simon Baron-Cohen
Am J Psychiatry 2009 166 (4)


  

  Commentary 
  

  Mental Illness, Work, and Income Support Programs 
  
Sheldon Danziger, Richard G. Frank and Ellen Meara
Am J Psychiatry 2009 166 (4)


  

  Treatment in Psychiatry 
  

  Postpartum Psychosis: Detection of Risk and Management 
  
Margaret G. Spinelli
Am J Psychiatry 2009 166 (4)


  

  Images in Psychiatry 
  

  Julius Wagner-Jauregg, 1857–1940 
  
Oliver D. Howes, Asha Khambhaita and Paolo Fusar-Poli
Am J Psychiatry 2009 166 (4)


  

  Reviews and Overviews 
  

  Treatment-Resistant Depression and Mortality After Acute Coronary Syndrome 
  
  
Robert M. Carney and Kenneth E. Freedland
Am J Psychiatry 2009 166 (4)


  

  New Research- Articles 
  

  Predictors of Spontaneous and Systematically Assessed Suicidal Adverse Events 
  in the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) Study 
  
  
David A. Brent, Graham J. Emslie, Greg N. Clarke, Joan Asarnow, Anthony Spirito, Louise Ritz, Benedetto Vitiello, Satish Iyengar, Boris Birmaher, Neal D. Ryan, Jamie Zelazny, Matthew Onorato, Betsy Kennard, Taryn L. Mayes, Lynn L. DeBar, James T. McCracken, Michael Strober, Robert Suddath, Henrietta Leonard, Giovanna Porta and Martin B. Keller
Am J Psychiatry 2009 166 (4)

Can Clinicians 
  Recognize DSM-IV Personality Disorders From Five-Factor Model Descriptions of 
  Patient Cases? 
  
Benjamin M. Rottman, Woo-kyoung Ahn, Charles A. Sanislow and Nancy S. Kim
Am J Psychiatry 2009 166 (4)

Identification of a Schizophrenia-Associated Functional Noncoding 
  Variant in NOS1AP 
  
Naomi S. Wratten, Holly Memoli, Yungui Huang, Anna M. Dulencin, Paul G. Matteson, Michelle A. Cornacchia, Marco A. Azaro, Jaime Messenger, Jared E. Hayter, Anne S. Bassett, Steven Buyske, James H. Millonig, Veronica J. Vieland and Linda M. Brzustowicz
Am J Psychiatry 2009 166 (4)

A Schizophrenia Gene Locus 
  on Chromosome 17q21 in a New Set of Families of Mexican and Central American 
  Ancestry: Evidence From the NIMH Genetics of Schizophrenia in Latino 
  Populations Study 
  
Michael Escamilla, Elizabeth Hare, Albana M. Dassori, Juan Manuel Peralta, Alfonso Ontiveros, Humberto Nicolini, Henriette Raventós, Rolando Medina, Ricardo Mendoza, Alvaro Jerez, Rodrigo Muńoz and Laura Almasy
Am J Psychiatry 2009 166 (4)

Altered Markers of Tonic Inhibition in the Dorsolateral Prefrontal 
  Cortex of Subjects With Schizophrenia 
  
Jaime G. Maldonado-Aviles, Allison A. Curley, Takanori Hashimoto, A. Leslie Morrow, Amy J. Ramsey, Patricio O’Donnell, David W. Volk and David A. Lewis
Am J Psychiatry 2009 166 (4)

Secretin Effects on 
  Cerebellar-Dependent Motor Learning in Schizophrenia 
  
Amanda R. Bolbecker, William P. Hetrick, Jason K. Johannesen, Brian F. O’Donnell, Joseph E. Steinmetz and Anantha S. Shekhar
Am J Psychiatry 2009 166 (4)

Reduced Neural Habituation in the Amygdala and Social Impairments in 
  Autism Spectrum Disorders 
  
Natalia M. Kleinhans, L. Clark Johnson, Todd Richards, Roderick Mahurin, Jessica Greenson, Geraldine Dawson and Elizabeth Aylward
Am J Psychiatry 2009 166 (4)

Maintenance Treatment for Patients With Bipolar I Disorder: Results 
  From a North American Study of Quetiapine in Combination With Lithium or 
  Divalproex (Trial 127) 
  
Trisha Suppes, Eduard Vieta, Sherry Liu, Martin Brecher, Bjorn Paulsson and Trial 127 Investigators
Am J Psychiatry 2009 166 (4)


  

  Communications and Updates- Letters to the Editor 
  

  Psychiatric Disorders and Repeat Offending 
  
Am J Psychiatry 2009 166 (4)

Psychiatric Disorders and Repeat Incarcerations: 
  
Am J Psychiatry 2009 166 (4)

Is There An Epidemic? 
  
Am J Psychiatry 2009 166 (4)

Potential Lower Efficacy of Molindone Among First-Generation 
  Antipsychotics 
  
Am J Psychiatry 2009 166 (4)

The Importance of the Main Effect Even Within an Interaction Model: 
  Elimination vs. Expansion of 
  
Am J Psychiatry 2009 166 (4)

Diagnostic Criteria for Depression 
  
Am J Psychiatry 2009 166 (4)

The Role of Epigenetics in Altered Gene Expression Involved in 
  GABAergic Transmission in the Cerebellum of Schizophrenia Patients 
  
Am J Psychiatry 2009 166 (4)

Mitochondrial Neurogastrointestinal Encephalomyopathy Mimicking 
  Anorexia Nervosa 
  
Am J Psychiatry 2009 166 (4)

Corrections 
  
Am J Psychiatry 2009 166 (4)

Corrected y coordinates 
  
Am J Psychiatry 2009 166 (4)

Corrected DOI 
  
Am J Psychiatry 2009 166 (4)


  

  Book Forum 
  

  Textbook of Psychotherapeutic Treatments 
  
Am J Psychiatry 2009 166 (4)

House Calls with William Carlos Williams 
  
Am J Psychiatry 2009 166 (4)

Mania: A Short History of Bipolar Disorder 
  
Am J Psychiatry 2009 166 (4)

Side Effects: A Prosecutor, a Whistleblower, and a Bestselling 
  Antidepressant on Trial 
  
Am J Psychiatry 2009 166 (4)

Books Received 
  
Am J Psychiatry 2009 166 (4)


Perspectives- Editorial

Teenaged, Depressed, and Treatment Resistant: What Predicts Self-Harm?

American Journal of Psychotherapy nr. 3

American Journal of Psychotherapy nr. 3

 

AMERICAN JOURNAL OF PSYCHOTHERAPY

Publicatie trimestriala
Traducere din limba engleza de Simona Reghintovschi
Nr. de pagini: 184
Pret: 30.00 Ron
Carte disponibila in librarii si online la
www.edituratrei.ro 


 

Din cuprinsul celui de-al treilea numar:

 

Rezultatele psihoterapiei in 40 de ani de practica privata

 Paul W. Clement, Ph.D., ABPP

Dintre 1969 de pacienti consultati de un psiholog clinician pe parcursul a 40 de ani de practica privata, in momentul analizarii datelor rezultatelor psihoterapiei, 1374 fie erau in tratament, fie incheiasera tratamentul si toate aceste cazuri oferisera date asupra rezultatelor terapiei. Rezultatele au aratat ca patru (4) pacienti (0,29%)  au evoluat mult mai rau, 10 (0,73%) au evoluat mai rau, 412 (22,96%) nu au prezentat nici o schimbare, 467 (33,96%) au evoluat mai bine 482 (35,06%) mult mai bine. Media marimii efectului tratamentului (ES) a fost de 1,87. Rezultatele tratamentului……

 

E-mail si psihiatrie: cateva perspective psihoterapeutice si psihanalitice 

C.G. Bhuvaneswar, M.D., T.G. Gutheil, M.D.

         In acest articol, luam in considerare utilizarea e-mailului in psihoterapie si impactul asupra experientei terapiei atat pentru pacient cat si pentru clinician. Discutam in detaliu potentialul de compromitere a limitelor prin utilizarea e-mailului si modul in care e-mailul poate submina alianta terapeutica si cultivarea empatiei. Studiile de caz ilustreaza posibilele aspecte pozitive ale e-mailului si elucideaza cateva probleme fundamentale ale oricarui tip de utilizare a e-mailului in tratamentul psihodinamic…

 

 

A da sens greselii: o perspectiva asupra originilor si tratamentului perfectionismului

Thomas S. Greenspon, Ph.D., LP, LMF

         Cercetarile asupra perfectionismului au lasat in general fara raspuns intrebarile despre istoria dezvoltarii sale si despre semnificatia pe care o are trairea lui. O vinieta clinica ilustreaza o abordare psihodinamica contemporana a raspunsului la aceste intrebari si o abordare terapeutica utilizata pentru a depasi perfectionismul si efectele sale impovaratoare asupra indivizilor si relatiilor intime. Progresele teoretice din psihologia relationala contemporana,  alaturi de experienta clinica a autorului ca psihoterapeut si consilier parental ofera materialul-sursa. Perfectionismul este inteles ca o dorinta de perfectiune, o frica de imperfectiune, echivalarea greselilor cu defecte personale si convingerea emotionala ca perfectiunea este calea catre a fi acceptat personal.

    

    

American Journal of Psychotherapy nr. 3

 

Atasament, reglare afectiva si sincronie mutuala in psihoterapia adultului

Thomas S. Greenspon, Ph.D., LP, LMFT Shelley Dales, M.C,.Paul Jerry, Ph.D.

 

            Acest articol examineaza teoria atasamentului in contextul biologiei reglarii afectelor si a convergentei acestora in procesele terapeutice. Ca urmare a progreselor recente in intelegerea modului in care creierul /mintea/corpul bebelusului sunt structurate de catre primele experiente sociale ale sale, scopul acestei investigatii este acela de a extrage acele mecanisme primare care largesc capacitatile reglatorii si adaptative si astfel de a reconsidera aplicarea lor in cadrul relatiei terapeutice. Dezvoltarile interdisciplinare indica faptul ca…

 

Analize subiective si intersubiective ale aliantei terapeutice in terapia relationala de scurta durata

Eyal Rozmarin, Ph.D., J. Christopher Muran, Ph.D., Jeremy Safran, Ph.D., Bernard Gorman, Ph.D., Jake Nagy, Ph.D.Arnold Winston, M.D.

 

            Obiectivul studiului descris in acest articol a fost de a construi o metoda de masurare a aliantei terapeutice dintr-o perspectiva intersubiectiva si de a evalua eficacitatea acestui instrument in predictia rezultatelor psihoterapiei…

 

Recenzii de carte

Jerome Kagan: What is Emotion? [Ce este emotia?] Yale University Press, New Haven

Antonia Orfield: Eyes for Learning: Preventing and Curing Vision – Related Learning Problems [Ochi pentru a invata: prevenirea si vindecarea problemelor de invatare legate de vedere] Rowman&Littlefield Education, Lanham, MD, 2007

 

 

Numarul 3 din American Journal of Psychotherapy poate fi achizitionat din librarii sau online de pe www.edituratrei.ro. Abonatii vor primi revista prin posta la sfarsitul saptamanii.

 

Material trimis de :

Viorel Vrabie
PR Psihologie Editura Trei
Tel./Fax: (021) 300 60 90
Mobil: 0726 152 156
viorel.vrabie@edituratrei.ro
www.edituratrei.ro

Medscape (Slides With Audio): Future Strategies for the Treatment of Osteoporosis

Medscape (Slides With Audio):

Future Strategies for the Treatment of Osteoporosis

Socrates E. Papapoulos, MD, PhD

 

Click pe :

 http://cme.medscape.com/viewarticle/588250

 

* Trebuie sa fiti `Log In` pe www.medscape.com

Medscape (Slides with Audio) : Current Therapeutic Agents

Medscape (Slides with Audio) :

Current Therapeutic Agents: Effectiveness, Limitations, and Concerns

John P. Bilezikian, MD

 

Click pe :

http://cme.medscape.com/viewarticle/588248

 

*Trebuie sa fiti `Log In` in www.medscape.com  

Metabolic Disorders Linked to Cognitive Decline

Metabolic Disorders Linked to Cognitive Decline

 


Allison Gandey

March 17, 2009 — Evidence is mounting that metabolic and neurological diseases share common risk factors. According to several reports in the March issue of the Archives of Neurology, metabolic disorders may influence the development of Alzheimer's disease and other forms of dementia.

"Preventing heart disease, stroke, and diabetes — or making sure these conditions are well managed in patients diagnosed with them — can potentially slow the disease progression of Alzheimer's," Yaakov Stern, PhD, from the Gertrude H. Sergievsky Center at Columbia University, in New York, said in a news release.

Dr. Stern is senior author of a paper in the issue exploring the effect of vascular risk factors on cognitive impairment.

In a review article in the same issue, Suzanne Craft, PhD, from the Veterans Administration Puget Sound Health Care System, in Seattle, Washington, reports, "In recent years, a rapidly increasing number of studies have focused on the relationship between dementia and metabolic disorders such as diabetes, obesity, hypertension, and dyslipidemia."

She points out that etiological heterogeneity and comorbidity pose challenges for determining relationships among metabolic disorders. "The independent and interactive effects of brain vascular injury and classic pathological agents such as beta amyloid have also proved difficult to distinguish in human patients, blurring the lines between Alzheimer disease and vascular dementia."

Few treatment options are available to improve prognosis. Dr. Stern and his team question whether controlling vascular conditions may be 1 way of delaying cognitive decline.

 

Control Vascular Risk Factors and Delay Alzheimer's?

The investigators hypothesized that vascular factors such as heart disease, stroke, diabetes, hypertension, smoking, and blood lipid levels may predict the progression of Alzheimer's disease.

Led by Elizabeth Helzner, PhD, also from Columbia University, the group studied 156 patients followed for a mean of 3.5 years. Participants were from the Washington Heights and Inwood Columbia Aging Project, a multiethnic, community-based, prospective study of aging in northern Manhattan.

Researchers found that patients with a history of diabetes and elevated levels of cholesterol, especially LDL cholesterol, had faster cognitive decline. In fact, each 10-U increase in cholesterol and LDL cholesterol was associated with a 0.10-standard-deviation decrease in cognitive score per year of follow-up (P < .001 for total cholesterol; P = .001 for LDL cholesterol).

Investigators found that a history of heart disease and stroke were associated with cognitive decline only in carriers of the APOE e4 allele.

"These findings indicate that controlling vascular conditions may be 1 way to delay the course of Alzheimer's, which would be a major development in the treatment of this devastating disease," Dr. Stern said.

In another study published in the issue, investigators show that obese middle-aged adults and underweight elderly people have an increased dementia risk.

 

Fluctuations in Weight May Boost Dementia Risk

Using data from the Cardiovascular Health Study, researchers studied the body-mass index (BMI) of participants at mid- and late life. Patients were from a community-dwelling sample at 4 US sites.

Investigators included 2798 people. Of these, 480 had incident dementia, 245 had Alzheimer's disease, and 213 had vascular dementia.

They found that middle-aged patients who were obese had an increased risk for dementia (BMI >30 vs normal-weight BMI 20 to 25), adjusted for demographics (hazard ratio, 1.39; 95% CI, 1.03 – 1.87) and for cardiovascular risk factors (hazard ratio, 1.36; 95% CI, 0.94 – 1.95).

 

These results help explain the 'obesity paradox.'

But the risk estimates were reversed in assessments of late-life BMI. Underweight people, those with a BMI of less than 20, had an increased risk for dementia (hazard ratio, 1.62; 95% CI, 1.02 – 2.64). Surprisingly, being overweight later in life was not associated with an increased risk (hazard ratio, 0.92; 95% CI, 0.72 – 1.18), and being obese reduced the risk for dementia (hazard ratio, 0.63; 95% CI, 0.44 – 0.91).

"These results help explain the 'obesity paradox,' " the researchers, led by Annette Fitzpatrick, PhD, from the University of Washington, in Seattle, write. "Differences in dementia risk across time are consistent with physical changes in the trajectory toward disability."

These findings suggest that the predictive ability of BMI changes across time, they note

"Weight loss occurs with comorbidities at older ages and is often reflective of poor health," write Dr. Fitzpatrick and her team. "Weight loss, along with psychological, behavioral, and mobility problems, is 1 of the principal manifestations of Alzheimer's disease. Weight loss may predate dementia onset by as much as 10 years."

The researchers conclude: "These results reinforce the necessity of monitoring weight loss closely in older adults."

The researchers have disclosed no relevant financial relationships.

Metformin May Up Alzheimer's Protein if Used Alone

Metformin May Up Alzheimer's Protein if Used Alone

 

Metformin Beta-Amyloid Effect Raises Alzheimer's Concerns

Janis Kelly

March 16, 2009 — Diabetes mellitus is associated with increased risk for Alzheimer's disease (AD), but a new study of metformin suggests that diabetes treatments might bear some of the blame.

Yaomin Chen, PhD, from the Burnham Institute for Medical Research, in La Jolla, California, and colleagues report in the March 10 issue of the Proceedings of the National Academy of Sciences that metformin increased insulin's reduction of intracellular and extracellular beta-amyloid accumulation, but metformin by itself actually increased levels of the Alzheimer's-linked peptides.

This finding, which was observed in vitro and in animal models of AD, raises the specter of a wave of new Alzheimer's cases in diabetic patients who have been taking metformin for years. It is the most popular antidiabetic drug in the United States and 1 of only 2 oral antidiabetics on the World Health Organization List of Essential Medicines (along with glibenclamide). In 2006, there were 35 million prescriptions for generic metformin filled in the United States.

Senior author Francesca-Fang Liao, PhD, told Medscape Psychiatry that although this was an animal study, the findings are worrisome enough that physicians should promptly follow up any complaints of cognitive decline in patients taking metformin.

"Our data suggest that metformin used alone might potentially facilitate development of AD pathology," Dr. Liao said. "This raised the question of whether the increased AD risk in diabetes mellitus patients might be due to the medication itself.

"Extensive animal studies as well as epidemiological data from clinical patients should be collected and carefully analyzed to address this question." Dr. Liao was at the Burnham Institute for Medical Research when this study was done but is now at the University of Tennessee Health Science Center, in Memphis.

Safer to Use Metformin in Combination Therapy?

The upregulation of beta-amyloid generation by metformin in animal models of AD occurred at steady-state plasma levels at and even below those reported in diabetic patients.

Metformin is an insulin-sensitizing drug, and the researchers found that giving it together with insulin added to insulin's known ability to reduce beta-amyloid generation.

"Our data suggest that the potentially deleterious effects of metformin to AD patients may be avoided by using it in combination with insulin; the combination may result in a beneficial effect in treating both type 2 [diabetes mellitus] and in mitigating AD progression," the researchers write.

AD expert Michal S. Beeri, MD, from the Mount Sinai School of Medicine, in New York, told Medscape Psychiatry, "The report by Chen is very interesting and consistent with a study from our group showing that brains of diabetics who, when alive, received combination therapy (ie, insulin plus an insulin sensitizer) had 80% less neuritic plaques (1 of the hallmark lesions of AD).

"This paper is also consistent with another study published in the Proceedings of the National Academy of Sciences [De Felice FG et al. Proc Natl Acad Sci. 2009;106:1971-1976] showing that soluble beta-amyloid oligomers (precursors of neuritic plaques) promote loss of surface of insulin receptor, that this loss can be prevented by insulin, and, most interesting, that adding the insulin sensitizer rosiglitazone [Avandia, GlaxoSmithKline] to insulin potentiates this protection.

"These studies suggest that there might be some protective mechanism that is triggered when the brain is exposed to insulin and insulin sensitizers at the same time, and this in turn has therapeutic potential," she said.

Randomized Control Trials Needed

With regard to the apparent deleterious effects of metformin, Dr. Beeri is more cautious, noting that large, placebo-controlled, double-blind trials will be required to establish that this happens in human patients as well as in animal models and in vitro.

"I think Chen's study is very important and strengthens the concept of diabetes medication effects on Alzheimer's neuropathology, but at this point I do not think that there is clinical evidence for clinicians to be concerned when treating their diabetic patients with metformin," she said.

The study was supported by National Institutes of Health grants, the Alzheimer's Association, and a Zenith Award. The authors report no conflicts of interest.

Proc Nat Acad Sci 2009;106:3907-3912.

Migraines in the Emergency Department: Which Therapy Is Best?

Migraines in the Emergency Department: Which Therapy Is Best?

 

Posted 03/12/2009

Knox H. Todd, MD, MPH
Author Information

Introduction

Patients with a complaint of headache accounted for 2.8% of all US emergency department (ED) visits in 2006 -- almost 3.4 million visits.[1] The vast majority of these visits were for primary headaches not secondary to underlying discrete causes such as meningitis or subarachnoid hemorrhage. After ruling out secondary causes and diagnosing a primary headache, the emergency physician must decide on therapy. Variations in therapy for migraine are substantial. In a 2002 study, Vinson[2] reported that 3 dozen agents alone or in combination, were commonly used in US EDs to treat migraine.

The ideal medication for migraine would be highly and rapidly effective, well tolerated, and inexpensive. Although parenteral triptans and opioids are often used for the treatment of primary headaches, antiemetic dopamine antagonists such as prochlorperazine and metoclopramide are among the most efficacious and available analgesics for migraine. Prochlorperazine and metoclopramide have few contraindications, do not cause significant orthostatic changes, and do not require cardiac monitoring. Because few comparative studies of these 2 drugs exist, most emergency physicians choose one or the other, based largely on personal preference. In 2 previous trials,[3,4] both published more than 10 years ago, prochlorperazine was felt to be the superior agent. However, doses of metoclopramide used in those studies may have been suboptimal.

A Randomized Controlled Trial of Prochlorperazine Versus Metoclopramide for Treatment of Acute Migraine

Friedman BW, Esses D, Solorzano C, et al.
Ann Emerg Med. 2008;52:399-406

 

Summary

In the October 2008 issue of the Annals of Emergency Medicine, Benjamin Friedman and his colleagues reported the results of their randomized, double-blind clinical trial that compared 10 mg of intravenous prochlorperazine with 20 mg of intravenous metoclopramide for the treatment of adults with acute migraine. Both agents were preceded by the administration of 25 mg of intravenous diphenhydramine to lessen the likelihood of akathisia, a side effect that is common with both study medications. The primary outcome measure was the change in pain intensity 1 hour after drug administration, measured by an 11-point numeric pain-rating scale. Secondary measures included achieving and sustaining a pain-free state within 2 hours, sustained normal functioning, and the need for rescue medication.

The investigators randomized 77 subjects in this trial over an 8-month period. In both arms of the study, pain intensity decreased markedly during the first hour after analgesic administration. Changes in pain scores tended to favor prochlorperazine; however, this result did not reach statistical significance. Although pain outcomes tended to favor prochlorperazine, adverse events were less common among patients receiving metoclopramide. More than 70% of subjects in both groups stated that they would want to receive the same treatment at future ED visits for migraine.

 

Viewpoint

Although this study was not large enough to detect statistically significant differences between prochlorperazine and metoclopramide, it does suggest that both agents are reasonably effective. In addition, this study is likely to popularize the use of metoclopramide at a higher dose (20 mg) than is traditionally used in the ED. In fact, the authors suggested that dose-ranging studies of metoclopramide are a reasonable next step for investigators working in this area. They also suggested that it is important to incorporate patient preferences in making analgesic choices. Given the frequency of repeat ED visits for migraines, this is a highly practical recommendation. Unless there are contraindications to their use, prochlorperazine or metoclopramide should be the first-line analgesics in the ED treatment of migraines.

Depression and Antidepressant Use Linked to Sudden Cardiac Death in Women

Depression and Antidepressant Use Linked to Sudden Cardiac Death in Women

 

from Heartwire — a professional news service of WebMD

Lisa Nainggolan

To earn CME related to this news article, click here.

March 9, 2009 (New York, New York) — A new analysis has found that major depression predicted cardiovascular morbidity and mortality in women participating in the Nurses' Health Study [1]. The hazard ratios were strongest for fatal events and were driven by the association of depression--in particular, antidepressant use--with sudden cardiac death (SCD). Dr William Whang (Columbia University, New York, NY) and colleagues report their findings in the March 17, 2009 issue of the Journal of the American College of Cardiology.

But the authors and accompanying editorialists conclude that, at the present time, the benefits of appropriately prescribed antidepressant use likely outweigh the risk of SCD.

"The absence of proof that antidepressants might cause cardiac events is more relevant than conclusive proof that this effect is absent. Nevertheless, these findings are sufficiently sobering to warrant heightened clinical surveillance and to initiate studies to definitively address this relationship," say Drs Sanjiv M Narayan and Murray B Stein (University of California, San Diego [UCSD]) in an accompanying editorial comment [2].

Whang told heartwire that he believes the biggest clinical implication of this new study "is that management of coronary heart disease risk factors may be especially important among women with depressive symptoms."

Those Using Antidepressants Three Times More Likely to Suffer SCD

Whang et al prospectively studied 63 469 women in the Nurses' Health Study without baseline coronary disease, stroke, or malignancy. They studied depressive symptoms and a proxy variable for clinical depression consisting of severe symptoms and/or antidepressant use and their relationship to cardiovascular events.

Questionnaires in 1992, 1996, and 2000 assessed depressive symptoms, with major depression defined by a validated five-point mental-health-index score (MHI-5) of <53, and antidepressant use was assessed in 1996 and 2000. Primary end points included SCD, fatal coronary heart disease (CHD), and nonfatal MI.

Of the women, 7.9% had MHI-5 scores of <53, previously found to predict clinical depression. Depressive symptoms were associated with CHD events, and the relationship was strongest for fatal CHD, with the association remaining significant even after researchers controlled for CHD risk factors (hazard ratio 1.49).

From 1996 onward, the proxy variable of severe symptoms and/or antidepressant use was most associated with SCD in multivariable models (HR 2.33), and the risk was primarily due to a specific relationship between antidepressant use and SCD (HR 3.34).

Narayan and Stein say the work of Whang et al stands out from previous research of this kind: "[This research] is particularly exciting. The authors should be congratulated for these important data on the etiologic role of depression and its treatment on cardiovascular outcomes in a very large cohort of healthy individuals."

Arrhythmia a Possible Mechanism, But Further Study Needed

"This surprising results merits scrutiny," the editorialists say. Numerous pharmaceutical agents might contribute to arrhythmic mortality, and in the present study, 61% of subjects were using selective serotonin-reuptake inhibitors (SSRIs), while 39% used other, nonspecified antidepressants.

"Our study raises questions about the mechanism by which depression is associated with sudden cardiac death," Whang told heartwire. "This is not the first study to link risk of SCD to depression. Our study is consistent with prior analyses that have found an association between depressive symptoms and a higher mortality in patients with CHD, and it points to arrhythmia as a possible mechanism for this worse prognosis."

Narayan and Stein say: "It is unclear whether SSRI agents might cause [sudden cardiac arrest]. While cardiac events are well documented with . . . tricyclic antidepressants, evidence for a link with SSRIs is mixed."

"Moreover, it is quite possible that antidepressant use merely indicates that depression is of sufficient severity to merit treatment." It is well established that patients with depression after acute coronary syndrome, for example, are less likely to adhere to their cardiac medication regimens, note the UCSD doctors, although treating the depression improves adherence.

"Clearly, the burden of proof rests on confirming this association. There are abundant data attesting to the safety and efficacy of SSRIs in particular, and a relative paucity showing adverse cardiac effects," they conclude.

Whang et al agree: "Although antidepressant medication use might be a marker of worse depression, its specific association with elevated risk of SCD merits further study."

Twin Study Shows Depression Itself Independently Associated With Heart Disease

Chicago, IL – Separately, new research suggests that depression itself remains a significant contributor to incident heart disease after genetics and environmental, mental, and physical factors are controlled for [3]. The study, performed in 1200 male twins who served in the US military during the Vietnam War, was reported by Dr Jeffrey F Scherrer (Washington University School of Medicine and St Louis Veterans Affairs Medical Center) at the American Psychosomatic Society meeting last week

"In this study, we have demonstrated that exposure to depression is contributing to heart disease only in twins who have high genetic risk and who actually develop clinical depression," says Scherrer in a Washington University School of Medicine statement.

"In twins with high genetic risk common to depression and heart disease but who never develop depression itself, there was no increased risk for heart disease. The findings strongly suggest that depression itself independently contributes to risk for heart disease," he notes.

Narayan reports receiving speaking honoraria or serving as a consultant for St Jude Medical, Boston Scientific, Medtronic, Biosense-Webster, and Cambridge Heart. Stein receives or has received in the past three years research support from Eli Lilly and GlaxoSmithKline and is currently or in the past three years has been a consultant for BrainCells, Bristol-Myers Squibb, Eli Lilly, EPI-Q, Forest Laboratories, Hoffman La-Roche Pharmaceuticals, Integral Health Decisions, Jazz Pharmaceuticals, Johnson & Johnson, Mindsite, Pfizer, Sanofi-Aventis, Sepracor, Transcept Pharmaceuticals, and Virtual Reality Medical Center.

  1. Whang W, Kubzansky LD, Kawachi I, et al. Depression and risk of sudden cardiac death and coronary heart disease in women. Results from the Nurses' Health Study. J Am Coll Cardiol 2009; 53:950-958
  2. Narayan SM and Stein MB. Do depression or antidepressants increase cardiovascular mortality? The absence of proof might be more important than the proof of absence. J Am Coll Cardiol 2009; 53:959-961
  3. Dryden J. Depression increases risk for heart disease more than genetics or environment [press release]. March 3, 2009. Available at: http://mednews.wustl.edu/news/page/normal/13643.html?emailID=23300.

Multidimensional aspects of depression

Multidimensional aspects of depression


The evolving understanding of depression

  • Treating MDD to remission is more complex than emotional symptom relief. Clinical studies have shown that:
  • Depression can have emotional, cognitive, behavioral, and painful somatic manifestations.1-3 The first 6 months of an episode of major depression are an important period in terms of treatment, and the probability of recovery decreases with increasing length of depressive illness4
  • Patients who experience residual subthreshold depressive symptoms—such as painful somatic symptoms—have been shown to be as much as 3 times more likely to relapse.5 In addition, patients with residual symptoms have been shown to have a shorter time to relapse than asymptomatic patients6

 

  • DSM-IV-TR: Multidimensional aspects of depression3

 
  • The ARTIST study, a naturalistic, randomized trial examining the treatment of clinical depression, showed that over time, emotional and somatic symptoms responded differently to antidepressant treatment.7 Among patients treated, somatic symptoms—in particular painful somatic symptoms—were more likely to persist7

Remission—how Cymbalta can help

Cymbalta demonstrated high rates of remission8

  • Cymbalta is effective, safe, and well-tolerated when taken as directed
  • Across 4 pooled studies in patients with major depressive disorder, high rates of remission were observed with a once-daily dose of Cymbalta8

Cymbalta 60 mg/day in MDD clinical trials:
Consistent rates of remission (HAM-D17≤7) across studies8

4 pooled studies
* P ≤.05, Cymbalta vs placebo in pooled analysis and 2 individual studies by MMRM
MMRM=Mixed-effects Models Repeated Measures analysis
Remission is different from response:
  • Remission is defined as a HAM-D17 Total Score of ≤7
  • Response is defined as a ≥50% decrease in HAM-D17 Total Score

Some days your patients may not feel like getting out of bed.
Find out how Cymbalta can help reduce the emotional symptoms of depression3  

 

 

Important Safety Information on Cymbalta® (duloxetine HCl)

Cymbalta is indicated in adults for:

  • The acute and maintenance treatment of major depressive disorder (MDD)
  • The acute treatment of generalized anxiety disorder (GAD)
  • The management of diabetic peripheral neuropathic pain (DPNP)
  • The management of fibromyalgia (FM)

 

Suicidality and Antidepressant Drugs—Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Cymbalta or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Cymbalta is not approved for use in pediatric patients.

 

Contraindications

  • Cymbalta should not be used in combination with MAOIs and is contraindicated for at least 14 days after discontinuation of an MAOI. After stopping therapy on Cymbalta, at least 5 days should be allowed before starting an MAOI.
  • Cymbalta was associated with an increased risk of mydriasis; therefore, it should not be used in patients with uncontrolled narrow-angle glaucoma and used cautiously in patients with controlled narrow-angle glaucoma.

Warnings and Precautions

  • Clinical Worsening and Suicide Risk
    All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially within the first few months of treatment and when changing the dose.
    Consider changing the therapeutic regimen, including possibly discontinuing the medication in patients whose depression is persistently worse or includes symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, or suicidality that are severe, abrupt in onset, or were not part of the patient’s presenting symptoms. If discontinuing treatment, the medication should be tapered. Families and caregivers of patients being treated with antidepressants for any indication should be alerted about the need to monitor patients.
  • Hepatic failure, sometimes fatal, has been reported in patients treated with Cymbalta. Cymbalta should be discontinued in patients who develop jaundice or other evidence of clinically significant liver dysfunction and should not be resumed unless another cause can be established.
  • Because it is possible that Cymbalta and alcohol may interact to cause liver injury or that Cymbalta may aggravate pre-existing liver disease, Cymbalta should ordinarily not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease.
  • Orthostatic hypotension and syncope have been reported with therapeutic doses of Cymbalta. Consideration should be given to discontinuing Cymbalta in patients who experience symptomatic orthostatic hypotension and/or syncope.
  • Development of a potentially life-threatening serotonin syndrome may occur with SNRIs and SSRIs, including Cymbalta treatment, particularly with concomitant use of serotonergic drugs, including triptans. Concomitant use is not recommended.
  • SSRIs and SNRIs, including Cymbalta, may increase the risk of bleeding events. Patients should be cautioned about the risk of bleeding associated with concomitant use of Cymbalta and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation.
  • On abrupt or tapered discontinuation, spontaneous reports of adverse events, some of which may be serious, have been reported during the marketing of SSRIs and SNRIs. A gradual reduction in dose rather than abrupt cessation is recommended when possible.
  • As with many antidepressants, Cymbalta should be used cautiously in patients with a history of mania or with a history of a seizure disorder.
  • In clinical trials across indications relative to placebo, treatment with Cymbalta was associated with mean increases of up to 2.3 mm Hg systolic and diastolic blood pressure. There was no significant difference in the frequency of sustained (3 consecutive visits) elevated blood pressure. Blood pressure should be measured prior to initiating treatment and periodically measured throughout treatment.
  • Co-administration of Cymbalta with potent CYP1A2 inhibitors or thioridazine should be avoided.
  • SSRIs and SNRIs, including Cymbalta, have been associated with cases of clinically significant hyponatremia that appeared to be reversible when Cymbalta was discontinued. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs.
  • The effect that alterations in gastric motility may have on the stability of the enteric coating of Cymbalta is unknown. As duloxetine is rapidly hydrolyzed in acidic media to naphthol, caution is advised in using Cymbalta in patients with conditions that may slow gastric emptying (eg, some diabetics).
  • Cymbalta should ordinarily not be administered to patients with any hepatic insufficiency or patients with end-stage renal disease (requiring dialysis) or severe renal impairment (creatinine clearance <30 mL/min).
  • As observed in DPNP trials, Cymbalta treatment worsens glycemic control in some patients with diabetes. In the extension phases (up to 52 weeks) of the DPNP studies, an increase in HbA1c in both the Cymbalta (0.5%) and the routine care groups (0.2%) was noted.
  • Cymbalta is in a class of drugs known to affect urethral resistance. If symptoms of urinary hesitation develop during Cymbalta treatment, this effect may be drug-related. In postmarketing experience, urinary retention has been observed.

Use in Specific Populations

  • Pregnancy and Nursing Mothers: Use only if the potential benefit justifies the potential risk to the fetus or child.

Adverse Events

  • The most commonly reported adverse events (≥5% and at least twice placebo) for Cymbalta vs placebo in controlled clinical trials (N=4843 vs 3048) were: nausea (25% vs 9%), dry mouth (14% vs 6%), somnolence* (11% vs 3%), constipation* (11% vs 4%), decreased appetite* (8% vs 2%), and increased sweating (7% vs 2%).
    *Events for which there was a significant dose-dependent relationship in fixed-dose studies, excluding three MDD studies that did not have a placebo lead-in period or dose titration.
  • In placebo-controlled clinical trials, the overall discontinuation rates due to adverse events were:
    MDD: 9% vs 5%; GAD: 15% vs 4%; DPNP: 14% vs 7%; FM: 20% vs 12%.

    The common adverse events reported as a reason for discontinuation and considered to be drug related were:
    MDD: nausea (1.3% vs 0.5%). GAD: nausea (3.7% vs 0.2%), vomiting (1.3% vs 0%), dizziness (1.0% vs 0.2%). DPNP: nausea (3.5% vs 0.4%), dizziness (1.6% vs 0.4%), somnolence (1.6% vs 0%), fatigue (1.1% vs 0%). FM: nausea (1.9% vs 0.7%), somnolence (1.5% vs 0%), fatigue (1.3% vs 0.2%).

References:

  1. Sheline YI. 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. Biol Psychiatry. 2000;48:791-800.
  2. Drevets WC. Functional neuroimaging studies of depression: the anatomy of melancholia. Annu Rev Med. 1998;49:341-361.
  3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington, DC: American Psychiatric Association; 2000.
  4. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry. 1992;49:809-816.
  5. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25:1171-1180.
  6. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50:97-108.
  7. Greco T, Eckert G, Kroenke K. The outcome of physical symptoms with treatment of depression. J Gen Intern Med. 2004;19:813-818.
  8. Data on file, Lilly Research Laboratories: CYM20060101C.
  9. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.  Neuropsychopharmacology. 2001;25:871-88.

AD/PD 2009: Europeans Create Common Brain Bank

AD/PD 2009: Europeans Create Common Brain Bank

 

Initiative Could Help Overcome Barriers to Research

Pauline Anderson

March 12, 2009 (Prague, Czech Republic) — European countries have worked closely together to create a common economic foundation and a common currency. Now they are collaborating on a common brain bank that promises to streamline access to brain specimens and overcome barriers to researching central nervous system (CNS) and psychiatric diseases. BrainNet Europe (BNE) is a network of 19 established brain banks in 13 countries across the continent.

Attendees of the 9th International Conference on Alzheimer's Disease (AD) and Parkinson's Disease (PD) learned that securing brains for research purposes is becoming increasingly difficult, as fewer autopsies are being carried out and ethical standards are becoming stricter.

Meanwhile, advances in the field have created increased demand for brain specimens, according to Hans A. Kretzschmar, MD, director of the Institute of Neuropathology, Brain-Net, German Reference Center for Diseases of the Central Nervous System, in Munich, Germany.

Access to human brain specimens is vital to the continued study of CNS disorders — especially in the wake of the human genome project. Indeed, some groundbreaking research would have been impossible without such access.

 

Autopsy Rate Declining Worldwide

"There's no doubt that many avenues of research would not have been possible in the absence of brains that were collected shortly after death," said Dr. Kretzschmar. As an example, he cited the discovery of a brain protein linked to amyotrophic lateral sclerosis (ALS) made possible only through brain banking. Such discoveries increase demand for brain specimens, but at the same time supply is decreasing, said Dr. Kretzschmar. "The autopsy rate is declining worldwide, so it's hard to get your hands on a specimen. Brains are hard to come by in this day and age."

Another reason for the declining supply of brain tissue is changing ethical standards. Whereas in the past it was relatively easy to secure such samples, today it often requires approval of relatives and possibly others, which can complicate and delay access to brain tissues. "This really makes for a dearth of brains," said Dr. Kretzschmar.

To help ensure the availability of high-quality brain-tissue samples, the European Union brought together brain banks from all over Europe in 2004. The new central brain bank joins a host of experienced experts and institutes in the field.

Among the main goals of the new consortium are to:

  • Promote brain banking as a research resource for European neuroscientists by providing high-quality human brain-tissue samples.
  • Determine the effect of pre- and postmortem parameters on preservation of DNA, RNA, and other substances.
  • Establish gold standards for tissue-handling quality control and ethics, leading to best practices for brain banking.
  • Provide training in brain banking and related methodology.
  • Promote future expertise in CNS research.

 

Implications for Psychiatric Illnesses

The BNE goes a long way toward harmonizing, sampling, and ensuring quality control, said Dr. Kretzschmar. At the same time, he said, the common database protects patient anonymity. "This all leads to high-quality brain banking."

Having access to a large number of brain-tissue specimens is advantageous for research not only into AD and PD but also into other diseases, including schizophrenia and other psychiatric illnesses, said Dr. Kretzschmar.

And allowing various research groups to access the same brain bank provides opportunities to network, he said, adding that it also has positive implications for access to Internet data banks.

That is not to say there are not some logistical barriers to overcome. One potential barrier is "the network of different laws" in the participating countries that govern tasks such s data collection, said Dr. Kretzschmar.

For example, some countries have relatively strict rules governing autopsies while others do not have any. Rules also vary on procedures such as informed consent. Dr. Kretzschmar said he would like to see more brain banks opened in the future.

The BNE Web site includes information for patients and donors as well as for scientists.

9th International Conference on Alzheimer's and Parkinson's Diseases: EU-sponsored session. Presented March 11, 2009.

Depression Lowers Blood Pressure, but Antidepressants Increase It

 

Psychiatry and Mental Health/Antipsychotic Treatment in Major Mental Illness
Pre-Activity Questionnaire
 
1. Atypical, or second-generation, antipsychotics as a group are:
Consistent in mechanism of action
Highly variable in their side-effect profiles
Uniformly more effective than first-generation antipsychotics in treating positive and negative symptoms
Significantly less likely to produce extrapyramidal side effects than are all first-generation antipsychotics.


 
2. "Atypical" antipsychotics are described as such because:
They are more effective in patients whose symptom clusters are uncommon
They have no effect on dopamine transmitters and are therefore distinct from earlier antipsychotic agents
They treat only negative symptoms
They are associated with a lower rate of extrapyramidal side effects than are earlier agents and therefore are distinct from earlier antipsychotic agents.

Depression Lowers Blood Pressure, but Antidepressants Increase It

Depression Lowers Blood Pressure, but Antidepressants Increase It

 

Tricyclics Could Be a Cause

Pauline Anderson


To earn CME related to this news article, click here.

March 3, 2009 — Contrary to prevailing opinion, new research indicates it is not depression that raises blood pressure but the drugs used to treat depression — a finding that suggests patients on antidepressants might need to be more closely monitored.

Investigators at the VU University Medical Center, in Amsterdam, the Netherlands, show that depression is associated with low — not high — blood pressure but that taking certain antidepressants, particularly tricyclic antidepressants (TCAs), tends to raise blood pressure and increase the risk for hypertension.

"Doctors should at least be aware of a potential blood-pressure rise that could be linked to TCA use, especially for patients with cardiovascular disease or high blood pressure or others who are at risk for hypertension," lead author Carmilla Licht, from the department of psychiatry at VU University Medical Center, told Medscape Psychiatry.

"They may consider meticulously monitoring these patients' blood pressure when they prescribe 1 of these antidepressants or consider prescribing another antidepressant medication."

The study is published online February 23 in Hypertension.

 

Contradicts Depression/Hypertension Theory

The study seems to contradict the theory that people with depression are more vulnerable to cardiovascular problems because their depression raises their risk for hypertension.

"We showed that depression itself was not associated with high blood pressure and hypertension, so the hypothesis does not seem to hold," said Licht, who is preparing her doctoral dissertation on the role of the autonomic nervous system in the relationship between depression (and anxiety) and cardiovascular diseases.

While the study found an association between low blood pressure and depression, it found a link between high blood pressure and anxiety.

Subjects for the study were part of the Netherlands Study of Depression and Anxiety, an ongoing analysis of 2981 adults aged 18 to 65 years. From this sample, 2618 subjects were included in the current study.

Participants were divided into 3 groups: a control group with no history of anxiety or depressive disorder (590); patients with a major depressive disorder (MDD) or an anxiety disorder who did not take antidepressants (1348); and patients with an MDD or an anxiety disorder who were on antidepressant medication. The researchers also differentiated between subjects with a remitted MDD or anxiety disorder and those with a current diagnosis.

In the group using antidepressants, researchers determined the number of patients taking the various drugs: 442 used selective serotonin-reuptake inhibitors (SSRIs); 67 used a TCA; and 135 used an antidepressant that works on noradrenergic and serotonergic (NS) systems.

To assess blood pressure, investigators averaged systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements taken twice during supine rest and adjusted these readings for use of hypertension medications.

They then created a 5-category hypertension indicator:

  • No hypertension (63.7% of study sample).
  • Isolated systolic hypertension (15.8%).
  • Isolated diastolic hypertension (2.7%).
  • Hypertension stage 1 (defined as SBP greater than or equal to 140 and DBP greater than or equal to 90) (13.1%).
  • Hypertension stage 2 (SBP greater than or equal to 160 and DBP greater than or equal to 100) (4.7%).

There was no difference in use of antihypertensives between the 3 groups.

 

No Association With SSRIs

Investigators also measured heart rate and respiratory sinus arrhythmia (RSA) and collected information on body-mass index and other variables including age, sex, and education. Compared with controls, subjects with a psychiatric disorder were a little older, more likely to be female, less educated, less physically active, smoked more, and had a higher body-mass index and more diseases.

Compared with healthy controls, patients with an MDD had a significantly lower mean SBP (remitted diagnosis: P = 0.02; current diagnosis: P = 0.002) and were less likely to have isolated systolic hypertension. Both remitted and current MDD was associated with lower SBP even after researchers corrected for antidepressant use, RSA, and heart rate.

Patients taking a TCA had up to a 9% higher mean SBP and an 11% higher mean DBP compared with healthy controls and nonmedicated patients. And they had about double the risk of having hypertension stage 1 and almost triple the risk of having hypertension stage 2.

The association between raised blood pressure and NS-working antidepressants was similar but weaker than that between TCAs and increased blood pressure. The use of SSRIs was not significantly associated with increased blood pressure or hypertension.

Does Low BP Cause Depression?

On the other hand, patients with anxiety had a significantly higher mean DBP than controls (P = 0.03), although this did not significantly raise the risk for isolated diastolic hypertension. These results remained after subjects using hypertension medication were excluded.

The study authors speculate on several possible reasons that depressed patients have low blood pressure. First, these patients may be more likely to use medications that treat hypertension, although this study did not find more users of these drugs in the groups with a psychiatric diagnosis, and results were similar when antihypertensive users were excluded from the analyses.

Another explanation could be that both depression and low blood pressure have a common cause. For example, a malfunction in metabolism that increases or decreases levels of certain metabolites, hormones, or neurotransmitters may affect both depression and blood pressure, said Ms. Licht.

Perhaps the most likely explanation is that low blood pressure may actually cause depression. People with low blood pressure are often tired, cold, and dizzy and have problems with concentration — symptoms that may cause depression, she said.

She added that the association may go both ways — individuals with low blood pressure may be more likely to become depressed, and those with depression may be more likely to develop low blood pressure.

Some previous research is not in agreement with these results. In fact, some studies found a positive association between depression and high blood pressure. But Ms. Licht believes the large sample size of the current study added weight to her results, as did taking into account the use of antidepressants.

In addition, she pointed out that while other studies focused on reports of depressive symptoms, this study included patients whose psychiatric diagnosis fulfilled Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV) criteria.

 

High BP Linked to Anxiety

As for the finding that anxiety is linked to high blood pressure, this might be due to the continuous stress experienced by people with anxiety. In such a state, the autonomic nervous system becomes dysfunctional, explained Ms. Licht.

"The sympathetic "fight, flight, and fright" response increases, and that raises the heart rate, while the parasympathetic 'rest and digest' response decreases, and that lowers heart-rate variability," she said, adding that both responses can influence blood pressure.

Why anxiety is associated only with DBP (and not SBP) is unclear, but might be related to the balance between sympathetic overactivity and parasympathetic underactivity in anxious people, said Ms. Licht.

It is too soon to say emphatically that TCAs actually cause hypertension and that these drugs should not be prescribed, Ms. Licht said. However, she said that there is enough research that strongly suggests TCAs and, to a lesser extent, NS-working drugs do play an important role in hypertension and dysregulation of the autonomic nervous system in depressed people.

"Doctors should clearly consider whether the beneficial effects of antidepressants on depression outweigh the effect of increasing blood pressure — and the possible increased risk for hypertension."

The authors report no disclosures.

Hypertension. Published online February 23, 2009

 

Overview of Obsessive-compulsive Disorder

From Medscape Psychiatry & Mental Health


Overview of Obsessive-compulsive Disorder:

An Expert Interview With Steven J. Brodsky, PsyD

 

Posted 02/16/2009

Laurie Barclay, MD
Author Information
Information from Industry
Could you help a depression patient achieve remission?
Learn about providing rapid relief from the core emotional symptoms of depression.
Read more

 

Editor's Note

Media attention on obsessive-compulsive disorder (OCD) has caused better recognition by the lay public as well as by clinicians, leading to an apparent increase in prevalence of this disorder. Recently recognized subtypes of OCD include scrupulosity, or OCD focused on religious practices or beliefs. Exposure-response prevention (ERP) is currently the most widely accepted treatment, and it is usually effective in compliant patients.

To learn more about the clinical presentation and management of OCD, Medscape interviewed Steven J. Brodsky, PsyD, a licensed clinical psychologist who specializes in cognitive behavioral therapy for OCD, phobias, and panic disorder. He is in solo practice in New York, NY.

Medscape: Is OCD on the rise, and/or are lay persons as well as clinicians now more aware of it?

Dr. Brodsky: People are definitely more aware of OCD; there's been much more media coverage in recent years. In light of that, it's difficult to determine if there's been an increase in prevalence of the condition. Just 15 years ago, OCD was not well understood -- now it has risen from relative obscurity to front-page news.

The statistics suggest that 2% of the population, which translates into 6 million people in the United States, have OCD.

Medscape: Please define and describe scrupulosity, or OCD as it manifests regarding religious practices and beliefs in persons of faith.

Dr. Brodsky: Each individual case varies, but generally speaking, scrupulosity can take a couple of different forms. Some specifically religious cases involve the person having negative thoughts or obsessions that they may have committed a sin within their faith. It could, for example, involve more ritualistic aspects, such as whether they prayed correctly, or an ethical code of conduct, for instance, honesty.

When a person thinks they might have sinned, they engage in a compulsion, or some kind of self-reassuring behavior. Either the individual will try to correct the situation they believe they committed by doing it over, for example, repeating their prayers, or by approaching the person they think they've mistreated. They may also try self-reassurance by trying to talk themselves out of the belief that they've sinned.

Other forms of scrupulosity may involve a feeling of being overly responsible for others, such as worrying about public safety issues. If they see something that they think could cause harm, they feel responsible to remove it from public exposure to safeguard other individuals.

Medscape: What are the consequences of OCD in terms of complications, comorbid conditions, and lost productivity?

Dr. Brodsky: OCD causes tremendous delay in activities and functions, which slows down productivity. The stress of OCD itself is exhausting and depletes people of their energy. Like all anxiety disorders, attention and memory are compromised. OCD accounts for a great deal of lost productivity and even absence from the work force entirely. There are people whose work is compromised or who are even disabled by OCD.

It is not uncommon for people with OCD to have comorbid attention-deficit disorder or tic disorders. Virtually everybody with OCD is depressed, at least secondarily to the OCD, which is a very frustrating condition.

Medscape: What treatment regimens or combinations of therapies do you think are most effective in OCD?

Dr. Brodsky: Research studies have shown that exposure response prevention (ERP) -- a form of psychotherapy -- is more effective than medication alone. In many cases, ERP may be even more effective than combined medication and ERP in terms of overall efficacy and relapse rates.

However, psychopharmacology may be helpful in more severe cases where people are overwhelmed because they are in a crisis or because they are unable to engage in ERP, which involves a certain amount of motivation and hard work. People who receive ERP are usually able to reduce or eliminate medication by the end of therapy.

Medscape: What is the status of currently available pharmacotherapy and drugs in development for OCD?

Dr. Brodsky: There are at least a dozen drugs that are used for OCD. The first strategy that is tried is use of selective serotonin reuptake inhibitors. Prozac®, Zoloft®, and Celexa® have been around longer; the more recent ones are Paxil®, Luvox®, and Lexapro®. An older drug is Anafranil®, a tricyclic antidepressant that may be associated with more side effects. When these fail, Effexor® is sometimes used.

Recently, in more complicated or severe cases, low-dose neuroleptics or supplements, such as inositol, a B vitamin, have enhanced the effectiveness of these medications.

Medscape: What is the prognosis for individuals with OCD, both untreated and with best available treatment?

Dr. Brodsky: With the best available treatment, I think the prognosis is quite good. Obviously, everything depends on the patient's compliance. The therapy itself is very collaborative -- it involves a lot of homework assignments on the part of the patient, several exposure exercises throughout the day. Usually these can be rather brief, but it does require a certain amount of discipline and motivation. If the client follows through, the prognosis is very good.

This assumes that the patient has received the right type of treatment. Unfortunately, the vast majority of people get no help at all. To be sure they're getting the right type of treatment, prospective patients can ask 2 test questions of their therapist. The first is: "Is ERP the therapist's main method of treating OCD?" Other treatments such as hypnosis or biofeedback are not even close in effectiveness.

The second question is, "How many patients with OCD have you successfully treated?" By successful, I mean that treatment pretty much got rid of most symptoms and that they were able to eliminate medication by the end of treatment.

Medscape: What additional research do you think needs to be done in OCD?

Dr. Brodsky: Certainly research to find medications for more severe cases and new approaches to work with more resistant patients who have certain comorbid conditions, such as an Axis II personality disorder, which can create resistance to therapy.

Successful treatment with levothyroxine

Successful treatment with levothyroxine for idiopathic hypersomnia patients with subclinical hypothyroidism
General Hospital Psychiatry, 03/24/09

Shinno H et al. - Hypersomnia may be associated with subclinical hypothyroidism, although few abnormalities in physical and neurological examinations are present. Methods

  • Sleep architecture and subjective daytime sleepiness were estimated by polysomnography (PSG) and Epworth Sleepiness Scale (ESS), respectively.
  • Diagnoses were made using the International Classification of Sleep Disorders, 2nd Edition criteria for idiopathic hypersomnia with long sleep time.

Results

  • PSG demonstrated a short sleep latency, a prolonged total sleep time and normal proportions of all non-rapid eye movement (REM) and REM sleep stages.
  • Nocturnal PSG excluded other causes of EDS.
  • No medical, neurological and mental disorders were present.
  • Mildly elevated thyrotropin, despite free thyroxine (T4) and triiodothyronine (T3) estimates within their reference ranges, which is a characteristic of latent hypothyroidism.
  • Levothyroxine (25g/day) was administrated orally. After treatment with levothyroxine for 8 weeks, the mean daily sleep times decreased.
  • EDS was also improved, and a significant decrease in the ESS score was observed. Levothyroxine was effective for their hypersomnia and well tolerated.

 

 

 

Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia
Human Psychopharmacology: Clinical and Experimental, 03/23/09

Henderson DC et al. - The addition of 160 mg/day of ziprasidone was well tolerated but did not produce significant improvement in fasting glucose, insulin resistance, hyperlipidemia or lead to weight loss in olanzapine- or clozapine-treated subjects with schizophrenia or schizoaffective disorder.

 

 

 

 

Blocked Enzyme Reverses Schizophrenia-like Symptoms
ScienceDaily, 03/20/09

Researchers at MIT's Picower Institute for Learning and Memory have found that inhibiting a key brain enzyme ireversed schizophrenia-like symptoms. Better understanding of the relationship could lead to new drug treatments for schizophrenia, the severe brain disorder that affects about 1 percent of the population and is characterized by hallucinations, delusions, poor social and emotional functioning and disorganized thoughts.

HOME (*Revenire-Pagina la Zi)

MENU

EDITORIAL